Life Tech and GSK to Co-Develop qPCR-Based Companion Dx for Investigative Cancer Immunotherapy
October 27, 2011
Life Tech and GSK to Co-Develop qPCR-Based Companion Dx for Investigative Cancer Immunotherapy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 1, 2011 / PCR Insider - Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy
March 4, 2010 / PCR Insider - GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009 / Pharmacogenomics Reporter - Life Tech Acquisition Would Make Thermo Fisher a Leader in PCR Research Tools, Forensic Analysis
April 18, 2013 / PCR Insider - Swedish Team, Life Tech Develop Method for qPCR Analysis of Proteins, RNA, DNA in Single Cells
October 18, 2012 / PCR Insider